New drug duo shows promise for rare blood cancer in early trial

NCT ID NCT04646395

First seen Apr 28, 2026 · Last updated May 15, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs, acalabrutinib and tafasitamab, in about 26 people with marginal zone lymphoma that has come back after prior treatment. The goal is to see how well the drugs shrink tumors and to check for side effects. Participants receive treatment for up to 24 cycles and are followed for about 3 years after the last dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ASST Spedali Civili di Brescia

    Brescia, Italy

  • AUSL Ravenna U.O. Ematologia

    Ravenna, 48121, Italy

  • Azienda Ospedaliera - IRCCS - Arcispedale Santa Maria Nuova

    Reggio Emilia, Italy

  • Fondazione IRCCS - Istituto Nazionale dei Tumori

    Milan, Italy

  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico

    Milan, Italy

  • Oncology Institute of Southern Switzerland

    Bellinzona, 6500, Switzerland

  • Ospedale Maggiore della Carità

    Novara, Italy

  • Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi

    Varese, Italy

  • University of Wien

    Vienna, 1190, Austria

Conditions

Explore the condition pages connected to this study.